Filing Analysis
Lisata Therapeutics has announced a massive 72% workforce reduction to reduce operating expenses and pursue strategic options. The filing also details the termination of its Chief Medical Officer, a $200,000 retention bonus for the CAO, and ongoing litigation against Kuva Labs Inc. regarding a breached merger agreement.
🚩 Red Flags
- Massive 72% workforce reduction indicates severe liquidity or operational distress.
- Litigation against a merger partner (Kuva Labs) suggests failed strategic growth/exit path.
- Termination of key R&D leadership (CMO) during a period of restructuring.
- Significant severance liabilities ($1.2M) impacting immediate cash position.
📋 Key Facts
- Workforce reduction of approximately 72% effective August 3, 2026.
- Estimated $1.2 million in severance and termination costs to be incurred through Q3 2026.
- Termination of Dr. Kristen K. Buck (EVP of R&D and Chief Medical Officer) without cause.
- Dr. Buck is entitled to 12 months of base salary, target bonus, and COBRA premiums.
- James Nisco (SVP, Finance and Treasury/CAO) granted a $200,000 cash retention bonus payable by Dec 31, 2026.
- Company is suing Kuva Labs Inc. in Delaware Court of Chancery for breach of a March 6, 2026 Merger Agreement.
Lisata Therapeutics has terminated its merger agreement with Kuva Labs Inc. after the acquirer failed to secure sufficient financing to complete the tender offer. The company is now exploring strategic alternatives, including a reverse merger or asset sales.
🚩 Red Flags
- Failed M&A transaction due to acquirer financing issues.
- Acquirer may lack the assets to satisfy potential legal judgments/damages.
- Company explicitly notes limited financial resources to fund related litigation.
- Board is now considering extreme strategic options including dissolution or reverse merger.
📋 Key Facts
- Merger Agreement dated March 6, 2026, between Lisata Therapeutics and Kuva Labs Inc. has been terminated.
- Termination triggered by Parent's failure to accept all validly tendered shares due to inability to obtain sufficient financing.
- Kuva Labs is required to pay a $2,000,000 termination fee to the Company.
- The original offer was $4.00 per share in cash plus CVRs totaling up to $3.00 per share.
- Company reserves rights to seek damages for 'Willful Breach' and enforcement costs.
Lisata Therapeutics has entered into an amendment to its existing Merger Agreement with Kuva Labs Inc. and its subsidiary, Kuva Acquisition Corp. The primary purpose of the amendment is to extend the 'Outside Date' for the merger transaction.
🚩 Red Flags
- Short extension window: The deadline was extended by only 4 days (from July 17 to July 21), suggesting potential delays in closing conditions or tender offer results.
📋 Key Facts
- The Amendment was entered into on July 16, 2026.
- The original Merger Agreement was dated March 6, 2026.
- The Outside Date of the merger has been extended from July 17, 2026, to July 21, 2026.
- The transaction involves a tender offer and a solicitation/recommendation statement (Schedule TO and Schedule 14D-9).
Lisata Therapeutics entered into an amendment to its Merger Agreement with Kuva Labs Inc. to extend the deadline for commencing a tender offer and the overall 'Outside Date' for the transaction. The amendment reveals that the purchaser has failed to meet previous deadlines and currently lacks committed financing.
🚩 Red Flags
- Lack of committed financing for the acquisition is explicitly disclosed.
- Purchaser has already missed a payment deadline (interim operating payment due May 26, 2026).
- Purchaser missed the original June 1 deadline to commence the tender offer.
- The company is granting waivers and covenants not to sue in exchange for delayed payments and extensions.
📋 Key Facts
- Tender offer commencement date extended from June 1, 2026, to June 10, 2026.
- The 'Outside Date' for the merger extended from July 1, 2026, to July 17, 2026.
- Parent may pay a non-refundable $1,500,000 extension fee to push the Outside Date to August 17, 2026.
- Purchaser failed to pay a $250,000 interim operating payment due on May 26, 2026; this will be cured via payments of $150,000 (June 12) and $100,000 (June 26).
- Purchaser explicitly acknowledged that the 'absence of committed financing' is material information for security holders.
Lisata Therapeutics reports that Kuva Labs Inc. (the Parent) will not commence the previously agreed-upon tender offer for Lisata's common stock on June 1, 2026. The Parent is currently renegotiating with financing sources, and there is no assurance that the offer will ever commence.
🚩 Red Flags
- Financing risk: The acquirer is unable to secure funding in time to meet the agreed-upon deadline.
- Deal uncertainty: The filing explicitly warns that the tender offer may never commence.
- Timeline slippage: The deal has already undergone at least one amendment to extend the deadline before this failure to launch.
📋 Key Facts
- A Merger Agreement was originally dated March 6, 2026.
- An amendment on May 29, 2026, extended the tender offer commencement date to June 1, 2026.
- On May 31, 2026, the Parent notified Lisata that it would NOT commence the offer on June 1, 2026.
- The delay is attributed to the Parent negotiating with potential financing sources.
- The company explicitly states there is 'no assurance as to when the Offer will commence, if at all.'
Lisata Therapeutics entered into an amendment to its merger agreement with Kuva Labs Inc., modifying the acquisition consideration and extending key transaction deadlines. The cash component of the offer was reduced, while the potential contingent value right (CVR) payments were increased and restructured.
🚩 Red Flags
- Reduction in guaranteed cash consideration (down $1.00 per share), shifting more value to contingent milestones.
- Extension of the Outside Date and tender offer commencement date suggests delays in the transaction timeline.
📋 Key Facts
- Cash offer price reduced from $5.00 per share to $4.00 per share.
- CVR structure changed from a single $1.00 payment to two potential payments totaling up to $3.00 ($1.25 for the First Milestone and $1.75 for the Second Milestone).
- First Milestone ($1.25) is tied to enrollment completion, 90% enrollment, or termination of the LSTA1-GBM-2A Phase 2a study.
- Second Milestone ($1.75) is tied to the filing or formal acceptance of a New Drug Application (NDA) for certepetide (LSTA1).
- Tender offer commencement date extended from May 29, 2026, to June 1, 2026.
- The 'Outside Date' for the merger was extended from July 1, 2026, to July 6, 2026.
Lisata Therapeutics has amended its merger agreement with Kuva Labs, extending the deadline for the commencement of a tender offer from April 13, 2026, to May 29, 2026. As part of the amendment, Kuva Labs has agreed to cover up to $1.1 million of Lisata's expenses while Lisata has waived claims related to the initial delay.
🚩 Red Flags
- The acquirer failed to meet the original deadline (April 13, 2026) for commencing the tender offer.
- The company is waiving legal claims against the acquirer for breach of the original timeline.
- The need for the acquirer to pay $1.1 million in operating expenses suggests potential liquidity pressure on the target company during the delay.
📋 Key Facts
- The original Merger Agreement was dated March 6, 2026.
- The deadline for Kuva Acquisition Corp. to commence the tender offer was extended from April 13, 2026, to May 29, 2026.
- Kuva Labs agreed to pay Lisata's expenses up to an aggregate of $1.1 million until the offer commences.
- Lisata agreed to a standstill on claims against Kuva relating to the delay until May 29, 2026.
- The waiver of claims becomes irrevocable once the offer commences and expenses are paid.
Lisata Therapeutics announced that Kuva Labs Inc. failed to commence its tender offer by the extended deadline of April 13, 2026. The acquirer is reportedly seeking alternative financing, and the company warned there is no assurance the deal will proceed.
🚩 Red Flags
- Missed multiple deadlines for tender offer commencement (April 3 and April 13).
- Acquirer is experiencing financing difficulties or seeking to renegotiate terms mid-transaction.
- Explicit disclosure that there is no assurance the tender offer will commence 'at all'.
📋 Key Facts
- Merger Agreement was originally signed on March 6, 2026.
- The deadline for the tender offer was first extended from April 3, 2026, to April 13, 2026.
- As of the filing date (April 15, 2026), the tender offer has not yet commenced.
- Parent company (Kuva Labs) is seeking 'alternative sources of financing on terms more favorable' to fund the offer.
- Lisata is currently in discussions with Kuva regarding the financing and timing.
Lisata Therapeutics and Kuva Labs Inc. have agreed to extend the commencement date of the tender offer for all outstanding shares of Lisata common stock. The deadline for the purchaser to start the offer was moved from April 3, 2026, to April 13, 2026.
🚩 Red Flags
- Delay in the commencement of a tender offer can indicate potential financing issues, regulatory hurdles, or last-minute due diligence concerns.
📋 Key Facts
- The original Merger Agreement was dated March 6, 2026.
- The extension was formalized via a waiver to the Merger Agreement on April 2, 2026.
- The tender offer commencement date is now April 13, 2026, a 10-day extension from the original April 3, 2026 date.
- Kuva Labs Inc. (Parent) and Kuva Acquisition Corp. (Purchaser) are the acquiring parties.
Lisata Therapeutics has entered into a definitive merger agreement to be acquired by Kuva Labs Inc. for $5.00 per share in cash plus a contingent value right (CVR) worth $1.00.
🚩 Red Flags
- Rollover stockholders (insiders/major holders) are receiving different treatment than retail shareholders by maintaining equity in the parent entity.
- The CVR is non-tradeable, limiting liquidity for the contingent portion of the merger consideration.
📋 Key Facts
- The acquisition is structured as a tender offer followed by a merger under Section 251(h) of the DGCL.
- Consideration includes $5.00 cash at closing plus one non-tradeable CVR representing a $1.00 milestone payment.
- The CVR milestone is triggered by the FDA filing or formal acceptance of a New Drug Application (NDA) for certepetide within seven years of closing.
- Certain 'Rollover Stockholders' have agreed to contribute their shares to the Parent entity rather than receiving the cash offer price.
- The transaction is not subject to a financing condition and is backed by a Capital Commitment Letter from a Capital Investor.
- In-the-money stock options, restricted stock, and RSUs will accelerate and vest upon the effective time of the merger.
Lisata Therapeutics has entered into an amendment to a binding term sheet with Kuva Labs Inc. to extend the negotiation period for a proposed acquisition of Lisata. The amendment extends the expiration date of the term sheet to March 7, 2026, to allow for the finalization of a definitive Purchase Agreement.
🚩 Red Flags
- The extension of the negotiation deadline suggests that the parties were unable to reach a definitive agreement within the timeframe originally contemplated.
- The transaction is subject to numerous closing conditions and the risk that a definitive agreement may not be reached.
📋 Key Facts
- Lisata and Kuva Labs Inc. are negotiating a transaction where Kuva will acquire all outstanding shares of Lisata via a tender offer.
- The original binding term sheet was dated January 20, 2026.
- On February 27, 2026, the parties signed an amendment extending the term sheet expiration to March 7, 2026.
- The proposed deal structure involves a tender offer followed by a short-form merger under Section 251(h) of the Delaware General Corporation Law.
- A definitive Purchase Agreement has not yet been executed.
Lisata Therapeutics has mutually terminated its Exclusive License and Collaboration Agreement with Qilu Pharmaceutical Co., Ltd. regarding the development and commercialization of certepetide in the Greater China territory.
🚩 Red Flags
- Loss of significant potential revenue stream (up to $200M in milestones and 10-15% royalties) in the Greater China market.
- Termination of a major collaboration with Qilu Pharmaceutical Co., Ltd. may signal strategic misalignment or lack of progress in that territory.
📋 Key Facts
- Termination effective date: January 23, 2026.
- The agreement covered research, development, and commercialization of certepetide (formerly CEND-1) in Greater China (Mainland China, Hong Kong, Macau, and Taiwan).
- Potential milestone payments under the original deal were valued at up to $200 million.
- Royalties under the agreement ranged from 10% to 15% on licensed product sales.
- The termination does not relieve parties of obligations accrued prior to January 23, 2026.
Lisata Therapeutics has entered into a binding term sheet with Kuva Labs Inc. for a potential acquisition via a tender offer and subsequent short-form merger. The deal includes a cash component of $4.00 per share plus two non-tradeable contingent value rights (CVRs) worth up to $2.00 each.
🚩 Red Flags
- CVRs are non-tradeable and contingent on future regulatory/regional events, making their actual value highly uncertain.
- The deal is subject to a 'no-shop' clause with a fiduciary out, allowing Lisata to seek superior proposals.
- The transaction is not yet a definitive Purchase Agreement; it is currently at the binding term sheet stage.
📋 Key Facts
- Acquisition price: $4.00 per share in cash.
- Additional consideration: Two non-tradeable CVRs of $1.00 each ($2.00 total).
- CVR 1 trigger: Rights to certepetide in the Greater China region revert to Lisata within 12 months.
- CVR 2 trigger: Filing of an NDA or similar registration for commercialization of certepetide in any jurisdiction.
- Kuva Labs has obtained funding commitments from third-party investors, though subject to diligence.
- A $2,000,000 breakup fee is applicable if the agreement is not entered into by February 27, 2026, under specific conditions.
- The Board of Directors unanimously supports the transaction.
Lisata Therapeutics, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2025. The filing includes a press release and a corporate presentation intended for investor conferences.
📋 Key Facts
- Reporting date: November 6, 2025
- Period covered: Third Quarter ended September 30, 2025
- Included Exhibits: Press Release (99.1) and Corporate Presentation (99.2)
- The information in Item 7.01 is furnished but not 'filed' for purposes of Section 18 liability.
Lisata Therapeutics, Inc. has issued a corporate slide presentation intended for use at investor and industry conferences. This filing is made pursuant to Item 7.01 to comply with Regulation FD disclosure requirements.
📋 Key Facts
- The Company issued a new corporate presentation on October 14, 2025.
- The presentation (Exhibit 99.1) is intended for use at investor and industry conferences.
- Information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liability.
Lisata Therapeutics entered into a worldwide non-exclusive license agreement with Catalent, Inc. to utilize the company's certepetide peptide as an ADC payload within Catalent's SMARTag platform. Under this deal, Catalent assumes all R&D and commercialization costs in exchange for licensing rights.
🚩 Red Flags
- Catalent maintains the right to terminate the agreement in its entirety at any time with 30 days' notice, creating significant uncertainty regarding long-term revenue stability.
📋 Key Facts
- Entered into a Non-Exclusive License Agreement with Catalent, Inc. on October 8, 2025.
- Catalent to assume full responsibility for research, development, and commercialization costs.
- Lisata is eligible for up to $10.5 million in aggregate pre-determined development milestone payments.
- Agreement includes tiered revenue sharing and a portion of sublicense consideration.
- Includes a Right of First Negotiation (ROFN) for Lisata if Catalent initiates an organized out-licensing process for assets resulting from the agreement.
Lisata Therapeutics, Inc. has filed an 8-K to announce its second quarter financial results for the period ended June 30, 2025. The filing includes a press release and a corporate presentation intended for investor conferences.
📋 Key Facts
- Reporting of Q2 2025 financial results (period ended June 30, 2025).
- Issuance of Exhibit 99.1: Press Release dated August 7, 2025.
- Issuance of Exhibit 99.2: Corporate Presentation dated August 7, 2025.
Lisata Therapeutics announced the issuance of a new USPTO patent (U.S. Patent No. 12,351,653) covering the composition of matter and pharmacokinetic properties of certepetide. The patent is expected to remain in effect until March 2040.
📋 Key Facts
- USPTO issued U.S. Patent No. 12,351,653 on July 8, 2025.
- Patent covers the composition of matter, chemical structure, and pharmacokinetic properties of certepetide.
- The patent expiration date is March 2040.
- Title of patent: 'PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL CYCLIC PEPTIDES'.
Lisata Therapeutics issued a press release regarding preliminary cohort B data from its Phase 2 ASCEND clinical trial. The trial is evaluating certepetide in combination with standard-of-care chemotherapy for metastatic pancreatic ductal adenocarcinoma.
📋 Key Facts
- Announcement of preliminary cohort B data from the Phase 2 ASCEND trial.
- Trial evaluates certepetide + standard-of-care chemotherapy.
- Indication: Metastatic pancreatic ductal adenocarcinoma.
- Data released via press release (Exhibit 99.1) and investor presentation (Exhibit 99.2).
Lisata Therapeutics updated its cash runway guidance, stating that available funds are now expected to support operations into the fourth quarter of 2026, an improvement from the third quarter of 2026 previously reported in their March 31, 2025, 10-Q.
🚩 Red Flags
- Ongoing reliance on existing cash reserves to fund operations (typical for biotech micro-caps).
📋 Key Facts
- Previous cash runway estimate: Operations supported into Q3 2026.
- Updated cash runway estimate: Operations supported into Q4 2026.
- As of March 31, 2025, the company had $25.8 million in cash, cash equivalents, and marketable securities.
Lisata Therapeutics, Inc. entered into several amended and restated employment and separation agreements for its top executives on June 10, 2025. The amendments primarily focus on updating base salaries, clarifying 'Change in Control' definitions to include shareholder-approved liquidations, and refining severance/COBRA benefit structures.
🚩 Red Flags
- Multiple executive compensation/separation amendments in a single filing (escalator: multiple items).
- Updates to 'Change in Control' definitions specifically including liquidation plans may suggest the company is preparing for or anticipating exit/liquidation scenarios.
📋 Key Facts
- CEO David Mazzo: Base salary increased from $633,032 to $717,229; non-accountable expense allowance of $12,000 removed.
- CMO Kristen Buck: Base salary increased from $550,000 to $599,342.
- All amended agreements (Mazzo, Buck, Nisco, Imam) updated the definition of 'Change in Control' to include shareholder approval of a complete liquidation plan.
- Amended terms for executives include specific provisions for COBRA reimbursement and lump-sum severance payments under Section 409A compliance.
Lisata Therapeutics, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on June 10, 2025. The meeting included votes on director re-elections, amendments to the employee stock purchase plan, auditor ratification, and advisory votes on executive compensation.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Re-election of Mohammad Azab, M.D., M.B.A. and Steven Klosk as Class III directors until 2028.
- Approval of an amendment to the 2017 Employee Stock Purchase Plan to increase available shares from 113,333 to 158,333.
- Ratification of Grant Thornton LLP as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Non-binding approval of executive compensation (Say-on-Pay).
- Approval of a one-year frequency for stockholder advisory votes on executive compensation.
Lisata Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing includes a press release and a corporate presentation intended for investor conferences.
📋 Key Facts
- Reporting period: First quarter ended March 31, 2025
- Filing date: May 8, 2025
- Included Exhibit 99.1: Press Release regarding financial results
- Included Exhibit 99.2: Corporate Presentation for investor/industry conferences
Lisata Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the fiscal year ended December 31, 2024. The filing includes a press release and a corporate presentation intended for investor conferences.
📋 Key Facts
- Report date: February 27, 2025
- Reporting period: Fiscal year ended December 31, 2024
- Included Exhibit 99.1: Press Release regarding financial results
- Included Exhibit 99.2: Corporate Presentation for investor/industry conferences
Lisata Therapeutics announced preliminary cohort A data from its ongoing Phase 2 ASCEND clinical trial evaluating certepetide in patients with metastatic pancreatic ductal adenocarcinoma. The company also provided a corporate presentation for investor use.
📋 Key Facts
- Announced preliminary Cohort A data from the Phase 2 ASCEND trial on January 22, 2025.
- The trial evaluates certepetide in combination with standard-of-care chemotherapy.
- Target indication is metastatic pancreatic ductal adenocarcinoma.
- Included a corporate presentation (Exhibit 99.2) for investor and industry conferences.
Lisata Therapeutics entered into an exclusive license and collaboration agreement with Kuva Labs, Inc. to develop and commercialize certepetide in combination with NanoMark™ imaging technology. Under the terms, Kuva assumes all R&D and commercialization costs while Lisata acts as a supplier.
🚩 Red Flags
- The agreement includes a termination clause allowing Kuva to terminate the agreement at any time with 60 days' notice, which reduces Lisata's long-term control over the asset.
📋 Key Facts
- Agreement dated November 30, 2024, with Kuva Labs, Inc. (a subsidiary of Mi2 Holdings, LLC).
- Upfront cash license fee: $1.0 million payable in four installments within 12 months.
- Development milestone payments: Up to $1.5 million based on regulatory milestones.
- Commercial milestone payments: Up to $17.5 million based on net sales milestones.
- Royalty structure: 5.0% flat-rate royalty on net sales of Licensed Products.
- Kuva assumes full responsibility for all research, development, and commercialization costs.
- Lisata is responsible for supplying certepetide under clinical and future commercial supply agreements.
Lisata Therapeutics, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2024. The filing includes a press release and a corporate presentation intended for investor conferences.
📋 Key Facts
- Reported date of event: November 12, 2024
- Financial results released for Q3 ended September 30, 2024
- Included Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation)
- The information in Item 7.01 is furnished but not 'filed' under Section 18 of the Exchange Act
Lisata Therapeutics, Inc. filed an 8-K to announce its second quarter financial results for the period ended June 30, 2024. The filing includes a press release and a corporate presentation intended for investor conferences.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Second quarter ended June 30, 2024
- Includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation)
- Information furnished under Item 7.01 is not considered 'filed' for purposes of Section 18 liability.
Lisata Therapeutics, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 27, 2024. Shareholders approved several key proposals including director re-elections and amendments to equity incentive plans.
🚩 Red Flags
- Significant opposition to the 'evergreen' provision in the equity plan (approx. 692k votes against).
📋 Key Facts
- Re-election of Class II directors: Gregory B. Brown, M.D., Heidi Henson, and David J. Mazzo, Ph.D.
- Approval of amendment to 2018 Equity Incentive Compensation Plan to increase shares by 600,000.
- Approval of a three-year 'evergreen' provision for the 2018 Equity Incentive Compensation Plan starting Jan 1, 2025.
- Increase in shares available under the 2017 Employee Stock Purchase Plan from 68,333 to 113,333.
- Ratification of Grant Thornton LLP as independent registered public accounting firm for FY2024.
- Non-binding advisory approval (Say-on-Pay) of executive compensation.
Lisata Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing includes a press release and a corporate presentation intended for investor conferences.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: First quarter ended March 31, 2024
- Included Exhibit 99.1: Press Release regarding financial results
- Included Exhibit 99.2: Corporate Presentation for investor/industry conferences
Lisata Therapeutics, Inc. announced the appointment of James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective April 15, 2024. Mr. Nisco will also serve as the Company's principal financial officer (PFO) and principal accounting officer (PAO).
📋 Key Facts
- James Nisco appointed as SVP, Finance and Treasury and Chief Accounting Officer effective April 15, 2024.
- Mr. Nisco will serve as the Company's principal financial officer and principal accounting officer.
- Annual base salary is set at $350,000 with a short-term incentive target of 35% of base salary.
- Nisco has been with the company since February 2012, previously serving as VP of Finance & Treasury and Senior Director of Treasury, FP&A.
Lisata Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing includes a press release and a corporate presentation used for investor conferences.
📋 Key Facts
- Reporting of financial results for the fiscal year ended December 31, 2023.
- The company issued a press release (Exhibit 99.1) regarding its financial condition.
- A corporate slide presentation (Exhibit 99.2) was provided for investor and industry conferences.